Immunotherapy for Gliomas: Part II Passive Immunotherapy and Active Immunotherapy

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Contemporary Neurosurgery

• Publication date

  2007-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.CNE.0000281044.08760.55
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

  2006cited by this paper
• Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma.

  2006cited by this paper
• Fas ligand expression and depletion of T-cell infiltration in astrocytic tumors

  2006cited by this paper
• Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

  2006cited by this paper
• Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors.

  2006cited by this paper
• Immunotherapy for human glioma: innovative approaches and recent results

  2005cited by this paper
• Impaired capacity for upregulation of MHC class II in tumor‐associated microglia

  2005cited by this paper
• Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma.

  2005cited by this paper
• Human Leukocyte Antigen and Antigen Processing Machinery Component Defects in Astrocytic Tumors

  2005cited by this paper
• Identification of EGFRvIII-derived CTL Epitopes Restricted by HLA A0201 for Dendritic Cell Based Immunotherapy of Gliomas

  2005cited by this paper
• Receptors and lytic mediators regulating anti‐tumor activity by the leukemic killer T cell line TALL‐104

  2005cited by this paper
• A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)

  2005cited by this paper
• Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines.

  2005cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.

  2005cited by this paper
• Delivery of Dendritic Cells Engineered to Secrete IFN-α into Central Nervous System Tumors Enhances the Efficacy of Peripheral Tumor Cell Vaccines: Dependence on Apoptotic Pathways1

  2005cited by this paper
• Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment

  2005cited by this paper
• Current status of therapy of solid tumors: brain tumor therapy.

  2005cited by this paper
• Pilot Study of Local Autologous Tumor Infiltrating Lymphocytes for the Treatment of Recurrent Malignant Gliomas

  2004cited by this paper
• Galectin-1 induces nuclear translocation of endonuclease G in caspase- and cytochrome c-independent T cell death

  2004cited by this paper
• Pharmacologic immunosuppression.

  2004cited by this paper
• Vaccination of Glioma Patients with Fusions of Dendritic and Glioma Cells and Recombinant Human Interleukin 12

  2004cited by this paper
• Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy after Vaccination

  2004cited by this paper
• Listeria-based cancer vaccines that segregate immunogenicity from toxicity.

  2004cited by this paper
• Analysis of Antitumor Activity of an Interleukin-13 (IL-13) Receptor-Targeted Cytotoxin Composed of IL-13 Antagonist and Pseudomonas Exotoxin

  2004cited by this paper
• Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cytotoxic T-Cells in Patients with Malignant Glioma

  2004cited by this paper
• Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-α. Results of a phase I clinical trial

  2004cited by this paper
• Recent advances in experimental molecular therapeutics for malignant gliomas.

  2004cited by this paper
• Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma

  2004cited by this paper
• Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.

  2004cited by this paper
• Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors.

  2004cited by this paper
• Dexamethasone Mediated Inhibition of Local IL-2 Immunotherapy is Dose Dependent in Experimental Brain Tumors

  2004cited by this paper
• CD4+ and CD8+ Regulatory T Cells Generated Ex Vivo with IL-2 and TGF-β Suppress a Stimulatory Graft-versus-Host Disease with a Lupus-Like Syndrome1

  2004cited by this paper
• Local Immunotherapy with Interleukin-2 Delivered from Biodegradable Polymer Microspheres Combined with Interstitial Chemotherapy: A Novel Treatment for Experimental Malignant Glioma

  2003cited by this paper
• Cytokine Immuno-Gene Therapy for Treatment of Brain Tumors

  2003cited by this paper
• Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.

  2003cited by this paper
• Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies.

  2003cited by this paper
• Progress Report of a Phase I Study of the Intracerebral Microinfusion of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-α and a Mutated form of the Pseudomonas Exotoxin Termed PE-38 (TP-38) for the Treatment of Malignant Brain Tumors

  2003cited by this paper
• A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor

  2003cited by this paper
• Adoptive transfer of an anti‐MART‐127–35‐specific CD8+ T cell clone leads to immunoselection of human melanoma antigen‐loss variants in SCID mice

  2003cited by this paper
• Treatment with allogeneic interleukin-2 secreting fibroblasts protects against the development of malignant brain tumors

  2003cited by this paper
• Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial

  2003cited by this paper
• Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma.

  2003cited by this paper
• Human CD4+CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation

  2003cited by this paper
• Tumor mRNA–loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma

  2003cited by this paper
• Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer

  2002cited by this paper
• Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

  2002cited by this paper
• Human CD4+CD25+ Regulatory, Contact-dependent T Cells Induce Interleukin 10–producing, Contact-independent Type 1-like Regulatory T Cells

  2002cited by this paper
• The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma.

  2002cited by this paper
• Human Autologous In Vitro Models of Glioma Immunogene Therapy Using B7-2, GM-CSF, and IL12

  2002cited by this paper
• IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein

  2002cited by this paper
• Application of interleukin-2–secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors

  2002cited by this paper
• A Phase II trial of intra‐cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis

  2002cited by this paper
• Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination.

  2002cited by this paper
• Cytotoxic T cells infiltrating a glioma express an aberrant phenotype that is associated with decreased function and apoptosis

  2001cited by this paper
• A phase III study of radiation therapy plus carmustine with or without recombinant interferon‐α in the treatment of patients with newly diagnosed high‐grade glioma

  2001cited by this paper
• Immune escape of gliomas.

  2001cited by this paper
• Galectin‐1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma

  2001cited by this paper
• Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.

  2001cited by this paper
• A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.

  2001cited by this paper
• Cutting Edge: Control of CD8+ T Cell Activation by CD4+CD25+ Immunoregulatory Cells

  2001cited by this paper
• Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.

  2001cited by this paper
• Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells

  2001cited by this paper
• Rapid entry and downregulation of T cells in the central nervous system during the reinduction of experimental autoimmune encephalomyelitis.

  2001cited by this paper
• Basic principles of immunological surveillance of the normal central nervous system

  2001cited by this paper
• Controlled Local Delivery of Interleukin-2 by Biodegradable Polymers Protects Animals from Experimental Brain Tumors and Liver Tumors

  2001cited by this paper
• Gene Therapy of Malignant Gliomas: A Pilot Study of Vaccination with Irradiated Autologous Glioma and Dendritic Cells Admixed with IL-4 Transduced Fibroblasts to Elicit an Immune Response

  2001cited by this paper
• In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures.

  2001cited by this paper
• The generation of anti-tumoral cells using dendritic cells from the peripheral blood of patients with malignant brain tumors

  2001cited by this paper
• Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts.

  2000cited by this paper
• Gene therapy of experimental brain tumors using neural progenitor cells

  2000cited by this paper
• Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.

  2000cited by this paper
• Targeted toxin therapy for malignant astrocytoma.

  2000cited by this paper
• T cell adoptive immunotherapy of newly diagnosed gliomas.

  2000cited by this paper
• A Pilot Study of Autologous Cancer Cell Vaccination and Cellular Immunotherapy Using Anti-CD3 Stimulated Lymphocytes in Patients with Recurrent Grade III/IV Astrocytoma

  2000cited by this paper
• The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.

  2000cited by this paper
• Human glioma immunobiology in vitro: implications for immunogene therapy.

  2000cited by this paper
• Immunotherapy with Dendritic Cells Directed against Tumor Antigens Shared with Normal Host Cells Results in Severe Autoimmune Disease

  2000cited by this paper
• The treatment of established intracranial tumors by in situ retroviral IFN-gamma transfer.

  2000cited by this paper
• Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors.

  2000cited by this paper
• Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.

  2000cited by this paper
• Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.

  2000cited by this paper
• The treatment of established intracranial tumors by in situ retroviral IFN-γ transfer

  2000cited by this paper
• Naive T lymphocytes traffic to inflamed central nervous system, but require antigen recognition for activation

  2000cited by this paper
• Antitumor effect and cellular immunity activation by murine interferon-β gene transfer against intracerebral glioma in mouse

  1999cited by this paper
• Immune defects observed in patients with primary malignant brain tumors.

  1999cited by this paper
• Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.

  1999cited by this paper
• Anti‐tumor activity of interleukin‐2‐producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system

  1999cited by this paper
• Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene.

  1999cited by this paper
• Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene.

  1998cited by this paper
• A new treatment for high grade gliomas of the brain.

  1998cited by this paper
• CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production

  1998cited by this paper
• Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.

  1998cited by this paper
• The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.

  1998cited by this paper
• Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity.

  1997cited by this paper
• Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model.

  1997cited by this paper
• Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment.

  1996cited by this paper
• Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy.

  1996cited by this paper
• Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas.

  1996cited by this paper
• Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.

  1996cited by this paper

• 19 – Management of recurrent gliomas and meningiomas

  2012cites this paper